Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 14 15 16 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Intellia Therapeutics–Cellex: allogeneic cell therapies, 202007– collab RnD genome editing + RevCAR technology for cancer + inflammation Gemoab 2020-07-20
CureVac–Germany (govt): investment, 202007 financing round Series B totalling €560m incl €300m from KfW approx 19% shareholding 2020-07-17
CureVac–GSK: investment, 202007 financing round Series B totalling €560m incl €150m from Glaxo Group Ltd 2020-07-17
CureVac–Qatar (govt): investment, 202007 financing round Series B totalling €560m incl €60m from Qatar Investment Authority 2020-07-17
CureVac–SEVERAL: investment, 202007 financing round Series B €560m incl €300m from KfW + €150m from GSK + €60m from QIA 2020-07-17
TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group 2020-07-16
Enancio–Illumina: acquisition, 202007 acquisition of Enancio by Illumina 2020-07-14
Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy 2020-07-09
CirQuest Labs–MLM Medical Labs: investment, 202007 acquisition of CirQuest Labs by MLM Medical Labs 2020-07-08
Osivax–Trophic Communications: public relations, 202007 service existent by Trophic Communications 2020-07-08
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
Molecular Partners–BVF Partners: investment, 202007 private placement totalling CHF80.2m with 5.53m new shares at CHF14.5/share 2020-07-06
Molecular Partners–Camber Capital Management: investment, 202007 private placement totalling CHF80.2m incl investor Camber Capital 2020-07-06
Molecular Partners–Federated Hermes Kaufmann Funds: investment, 202007 private placement totalling CHF80.2m incl investor FHKF 2020-07-06
Molecular Partners–Monashee Investment Management: investment, 202007 private placement totalling CHF80.2m incl investor Monashee 2020-07-06
Molecular Partners–SEVERAL: investment, 202007 private placement CHF80.2m from new + existing European + US institutional investors 2020-07-06
Molecular Partners–Suvretta Capital: investment, 202007 private placement totalling CHF80.2m incl investor Suvretta Capital Management 2020-07-06
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
Bright Peak Therapeutics–SEVERAL: investment, 202007 financing round Series A $35m 2020-07-01
Resolution Spectra Systems–Merck (DE): investment, 202007 acquisition €na of Resolution Spectra Systems by Merck 2020-07-01
Roche–Inveox: sample management software, 202007– collab digitization Vantage Workflow Solution for histopathology labs with Roche Diagnostics 2020-07-01
Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters 2020-07-01
DeepSpin–Apex Ventures: investment, 202006 seed financing round totalling €600k incl new + lead investor Apex Digital Health 2020-06-30
DeepSpin–Entrepreneur First: investment, 202006 seed financing round totalling €600k incl existing + co-investor EF 2020-06-30
DeepSpin–OTHER: investment, 202006 seed financing round totalling €600k incl several business angels 2020-06-30
DeepSpin–SEVERAL: investment, 202006 seed financing round €600k from Apex Digital Health + EF + SOSV + business angels 2020-06-30
DeepSpin–SOSV: investment, 202006 seed financing round totalling €600k incl existing + co-investor SOSV 2020-06-30
CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share 2020-06-29
Cutiss–Gisev Family Office: investment, 202006 financing round Series B totalling CHF20m incl lead investor Gisev Familiy Office 2020-06-29
Cutiss–SEVERAL: investment, 202006 financing round Series B CHF20m led by Gisev Familiy Office 2020-06-29
ArcherDx–Invitae: investment, 202006– acquisition merger up to $1.4b with $325m cash + 30m shares + up to addit 27m shares milestone-dependent 2020-06-22
RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion 2020-06-22
Kaia Health–SEVERAL: investment, 202006 financing round Series B $26m led by Optum Ventures + Idinvest + capital300 2020-06-18
Univ Bochum–Max Planck: antibiotics research, 202006– collab establishment CESAR Center for Antibiotics Research at Univ Bochum with LDC 2020-06-18
Univ Bochum–North Rhine-Westphalia (govt): grant, 202006– grant €4m from NRW + EFRO for establishment CESAR Center for Antibiotics Research with LDC 2020-06-18
C4 Therapeutics–SEVERAL: investment, 202006 financing round Series B $150m co-led by Cobro Ventures + Perceptive Advisors 2020-06-16
DiogenX–Boehringer: investment, 202006 seed financing round totalling €4.5m incl investor BIVF 2020-06-16
DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund 2020-06-16
eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF 2020-06-16
eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors 2020-06-16
Qurient–Max Planck: proteasome inhibitors, 202006– collab develop + license + founding of joint venture QLi5 Therapeutics GmbH 2020-06-16
Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital 2020-06-13
Bit Bio–Mission Group: public relations, 202006 service existent by April Six 2020-06-13
Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum 2020-06-13
Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine 2020-06-12
10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma 2020-06-09
Tolremo Therapeutics–Altos Venture: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-lead investor Altos 2020-06-09
Tolremo Therapeutics–BioMedPartners: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-lead investor BMP 2020-06-09
Tolremo Therapeutics–OTHER: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing private biotech investors 2020-06-09
Tolremo Therapeutics–Redalpine: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-investor Redalpine VP 2020-06-09
Tolremo Therapeutics–SEVERAL: investment, 202006 financing round Series A 2nd closing CHF4.7m bringing total Series A to CHF13.7m 2020-06-09
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 202006 financing round Series A 2nd closing totalling CHF4.7m incl existing + co-investor ZKB 2020-06-09
Koehler eClinical–Excelya: investment, 202007 acquisition 2020-06-07
Everest Medicines–SEVERAL: investment, 202006 financing round Series C $310m led by Janchor Partners + co-led by RA CApital + Hillhouse Capital 2020-06-04
BRAIN Biotech–SEVERAL: investment, 202006 private placenment €14.94m with 1.8m new shares at €8.3/share 2020-06-03
AdvanceCor–Bavaria (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor Bayern Kapital 2020-06-02
AdvanceCor–First Capital Partner: investment, 202006 financing round totalling €3.9m incl co-investor First Capital Partner 2020-06-02
AdvanceCor–Germany (govt): investment, 202006 financing round totalling €3.9m incl existing + co-investor KfW Bank 2020-06-02
AdvanceCor–MIG Fonds: investment, 202006 financing round totalling €3.9m incl existing + lead investor MIG AG 2020-06-02
AdvanceCor–Occident: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident 2020-06-02
AdvanceCor–SEVERAL: investment, 202006 financing round €3.9m led by MIG AG 2020-06-02
Corat Therapeutics–Lower Saxony (govt): investment, 202006 1st financing round incl existing investor NBank Capital 2020-06-01
Corat Therapeutics–OTHER: investment, 202006 1st financing round incl private investors from Braunschweig 2020-06-01
Corat Therapeutics–SEVERAL: investment, 202006 1st financing round from NBank Capital + private investors 2020-06-01
Rigenerand–Image Box: public relations, 202005– supply service by Image Box PR 2020-05-29
Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility 2020-05-27
KI-SIGS project–Germany (govt): grant, 202005– funding €10m from German federal government 2020-05-27
Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital 2020-05-27
Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF 2020-05-27
Kumovis–Renolit: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Renolit SE 2020-05-27
Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures 2020-05-27
Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures 2020-05-27
Exscientia–Evotec: investment, 202005 financing round Series C totalling $60m incl existing + co-investor Evotec 2020-05-26
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202005 discloses financing round Series A totalling $32.5m incl investor NEA 2020-05-26
Monte Rosa Therapeutics–SEVERAL: investment, 202005 emerges from stealth + discloses financing round Series A $32.5m from Versant + NEA 2020-05-26
Monte Rosa Therapeutics–Versant Ventures: investment, 202005 discloses financing round Series A totalling $32.5m incl founding investor Versant 2020-05-26
Spindiag–Baden-Württemberg (govt): grant, 202004 grant €6m for Spindiag + HSI-IMIT from Ministry of Economic Affairs 2020-05-26
Spindiag–SEVERAL: investment, 202005 financing round Series B €16.3m with investors WBG Pflegeheime + Think-Health Ventures et al. 2020-05-26
Spindiag–Think.Health Ventures: investment, 202005 financing round Series B totalling €16.3m incl new investor Think.Health Ventures 2020-05-26
Spindiag–WBG Pflegeheime: investment, 202005 financing round Series B totalling €16.3m incl existing investor WBG Pflegeheime 2020-05-26
Sterna Biologicals–MC Services: public relations, 202005 service existent by MC Services 2020-05-26
Sterna Biologicals–SEVERAL: investment, 202005 financing round Series A first closing €12m with existing + new investors 2020-05-26
Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary 2020-05-26
Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications 2020-05-25
Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche 2020-05-22
Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors 2020-05-19
Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins 2020-05-19
Rentschler–MC Services: public relations, 202005 service existent by MC Services 2020-05-19
Roche–Vividion Therapeutics: drug discovery, 202005– collab ww excl option + license agreem $135m upfront small molecules targeting E3 ligases 2020-05-19
Apeiron–Austria (govt): grant, 202005– grant funding + guarantees €5.6m from FFG + WAW + AWS + Erste Bank 2020-05-18
Apeiron–SEVERAL: investment, 202005–202006 private placement €11.9m led by Vienna Insurance Group plus existing + new investors 2020-05-18
Apeiron–Vienna Insurance Group: investment, 202005–202006 private placement totalling €11.9m incl €7m from new + lead investor VIG 2020-05-18
Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon 2020-05-16
OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader 2020-05-16
Ori Biotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori 2020-05-13
Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch 2020-05-13
Bluebird Bio–Showa Denko: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies 2020-05-11
next pagenext page 1 2 3 ... 14 15 16 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px

» top